Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2020-11-12 Earnings Release
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 11, 2020, by Pacira BioSciences, Inc. It announces preliminary unaudited revenue for the month ended October 31, 2020, and includes a press release as an exhibit. The document is short (3430 characters) and primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis. It fits the description of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER).
2020-11-12 English
10-Q - PCRX - 9.30.2020
Interim / Quarterly Report Q3 2020
2020-10-30 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing its financial results for the third quarter ended September 30, 2020. It also references the press release as Exhibit 99.1. The document does not contain the full financial statements or detailed financial analysis itself but rather announces the earnings release. The length is 3392 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER).
2020-10-29 English
FORM 4 SUBMISSION
Director's Dealing
2020-10-16 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 7, 2020, by Pacira BioSciences, Inc. It announces preliminary unaudited revenue for the month and quarter ended September 30, 2020, and includes a press release as an exhibit. The document is short (3439 characters) and primarily serves as a current report to announce financial results, not a full financial report. It is an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER).
2020-10-07 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.